Ticker Details
VistaGen Therapeutics, Inc. VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
IPO Date:	July 1, 2011
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$10.23M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.10 | 5.44%
Avg Daily Range (30 D):	$0.05 | 7.52%
Avg Daily Range (90 D):	$0.03 | 5.42%

Institutional Daily Volume
Avg Daily Volume:	.23M
Avg Daily Volume (30 D):	3.14M
Avg Daily Volume (90 D):	1.56M

Trade Size
Avg Trade Size (Sh.):	105
Avg Trade Size (Sh.) (30 D):	553
Avg Trade Size (Sh.) (90 D):	460

Institutional Trades
Total Institutional Trades:	84
Avg Institutional Trade:	$2.29M
Avg Institutional Trade (30 D):	$.59M
Avg Institutional Trade (90 D):	$.59M
Avg Institutional Trade Volume:	.22M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.82M
Avg Closing Trade (30 D):	$.76M
Avg Closing Trade (90 D):	$.76M
Avg Closing Volume:	147.97K

News

Jun 1, 2026 @ 6:40 PM Kuehn Law Encourages Investors of Vistagen Therape... Source: Kuehn Law, Pllc

Mar 14, 2026 @ 10:01 PM VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL,... Source: Rosen Law Firm

Mar 12, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Vistagen T... Source: Bronstein, Gewirtz & Grossman Llc

Mar 9, 2026 @ 2:00 PM VTGN Investors Have Opportunity to Lead Vistagen T... Source: The Schall Law Firm

Mar 7, 2026 @ 2:14 PM VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM... Source: Rosen Law Firm

Financials
	TTM	Q4 2026	FY 2026
Basic EPS	$-1.83	$-.37	$-1.83
Diluted EPS	$-1.83	$-.37	$-1.83
Revenue	$1.27M	$.47M	$1.27M
Gross Profit
Net Income / Loss	$-69.69M	$-16.27M	$-69.69M
Operating Income / Loss	$-72.13M	$-16.72M	$-72.13M
Cost of Revenue
Net Cash Flow	$-36.34M	$-16.58M	$-36.34M
PE Ratio

Splits
Jun 07, 2023	1:30
Aug 14, 2014	1:20
Jun 10, 2011	2:1